---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Androgen deprivation therapy"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Androgen deprivation therapy. Topics: Continued castration in metastatic castration-resistant disease: guideline statements, Continued castration in hormone-refractory disease: treatment summary, Concurrent gonadotropin-releasing hormone analog or orchiectomy in androgen receptor pathway inhibitor labeling, and Continued androgen deprivation in post-inhibitor trials. 4 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/androgen-deprivation-therapy"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Androgen deprivation therapy

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Androgen Deprivation Therapy

<a id="topic-2.2.2.1.1-1"></a>

### Continued castration in metastatic castration-resistant disease: guideline statements

> “However, in the absence of prospective data, the modest potential benefits of continuing castration outweigh the risk of treatment.”
> “In addition, all subsequent treatments have been studied in men with ongoing androgen suppression, therefore, it should be continued in these patients.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.1-2"></a>

### Continued castration in hormone-refractory disease: treatment summary

> “Patients treated with either luteinizing-hormone agonists or estrogens as primary therapy are generally maintained with castrate levels of testosterone.”
> “One study from the Eastern Cooperative Oncology Group (ECOG) showed that a superior survival resulted when patients were maintained on primary androgen deprivation”
> “another study from SWOG (formerly the Southwest Oncology Group) did not show an advantage to continued androgen blockade.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.2.1.1-3"></a>

### Concurrent gonadotropin-releasing hormone analog or orchiectomy in androgen receptor pathway inhibitor labeling

> “Patients receiving XTANDI for castration-resistant prostate cancer, or metastatic castration-sensitive prostate cancer should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.”

Source: [Xtandi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203415s026lbl.pdf)

> “Patients receiving ZYTIGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.”

Source: [Zytiga prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202379s035lbl.pdf)

> “Patients receiving NUBEQA should also receive a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or have had a bilateral orchiectomy.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.2.2.1.1-4"></a>

### Continued androgen deprivation in post-inhibitor trials

> “Patients were required to be surgically or medically castrated with a castrate level of serum testosterone at study entry.”
> “If patients were being treated with androgen deprivation therapy (ADT), therapy was continued throughout the study.”

Source: [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf)

> “All patients maintained castration therapy during the trial.”

Source: [de Bono et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28844372/)

Additional sources: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer); [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
